PLK1 and cancer: Through the inhibition of PLK1, cancer cells are selectively killed, and PD-L1 expression is upregulated in surviving cancer cells, resulting a feedforward targeted delivery of ARAC using PD-L1 antibody-conjugated nanoparticles.